Full-Time

Microfluidics Engineer

Posted on 9/19/2025

Vital Biosciences

Vital Biosciences

201-500 employees

Desktop-based automated point-of-care blood testing platform

No salary listed

Oakville, ON, Canada

In Person

Category
Biology & Biotech (2)
,
Requirements
  • Masters or Ph.D. degree in Bioengineering, Mechanical Engineering, Material Science or a related discipline
  • Extensive hands-on experience and a proven track record with microfluidic systems
  • Intimate knowledge of microfluidics materials and manufacturing processes
Responsibilities
  • Design, develop, model, fabricate, and test innovative microfluidic sample handling systems
  • Utilizing above microfluidic systems for medical or diagnostics systems (IVD)
  • Transfer methods to other internal or external partners and support the collaboration through timely result analysis
  • Communicate analytical results to peers and leadership to support decision-making, and collaborate with development teams to support goals and timelines
Desired Qualifications
  • 2+ years of industry experience, specifically relating to product development of IVD systems, is preferred
  • Knowledge of chemistry-based surface modification and related areas
  • Broad knowledge of material science, immunology, microbiology and other related fields
  • Proficient with general purpose computation software (Python, etc.) and other data analysis tools
  • Working knowledge of Good Laboratory Practices

Vital Bio (VitalOne) is a health-tech company that makes a desktop-sized, automated point-of-care diagnostics platform. It performs 50+ lab-grade tests from 600 microliters of blood in about 20 minutes, enabling testing, diagnosis, and treatment within a single visit for settings like primary care clinics, pharmacies, and in-home care. The system combines microfluidics, robotics, computer vision, and biochemistry to run hematology, clinical chemistry, and immunoassays in parallel, with under 30 seconds of hands-on time and a patient app for result tracking. Unlike traditional centralized labs or smaller POCT devices, Vital One covers roughly 95% of routine lab orders and aims to reduce delays and improve accessibility, pursuing a goal of making diagnostics readily available where patients receive care.

Company Size

201-500

Company Stage

Early VC

Total Funding

$48M

Headquarters

Mississauga, Canada

Founded

2018

Simplify Jobs

Simplify's Take

What believers are saying

  • Point-of-care testing closes care gaps by enabling test-diagnose-treat in single visit.[2]
  • $62 million raised through September 2024 from top-tier investors including Sam Altman.[3]
  • Global expansion to Boston, San Francisco, and Portugal accelerates market penetration beyond Canada.[1]

What critics are saying

  • VitalOne lacks FDA clearance as of April 2026, blocking US market entry entirely.[2]
  • Established competitors like Abbott i-STAT Alinity dominate POC testing with proven reimbursement.[1]
  • No product revenue by mid-2026 despite $62M raised suggests unsustainable burn rate trajectory.[1]

What makes Vital Biosciences unique

  • VitalOne performs 50+ lab-grade tests from 600 microliters blood in 20 minutes.[2][3]
  • Proprietary centrifugal microfluidics platform with computer vision quality control embedded throughout.[5]
  • Desktop device requires less than 30 seconds hands-on time for clinical staff operation.[1]

Help us improve and share your feedback! Did you find this helpful?

Benefits

Competitive compensation and benefits package

Professional Development Budget

Conference Attendance Budget

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

3%

2 year growth

0%
Longevity.Technology
Jul 27th, 2023
Vital Biosciences raises $48m for revolutionary blood diagnostic tech

Backers include Sam Altman and Marc Benioff as company seeks to create accessible diagnostics and expedite clinical interventions.

BetaKit
Jul 26th, 2023
Vital Biosciences reveals blood-testing solution

After the bloody mess at Theranos, Vital is among the new wave of startups developing accessible diagnostics.

Bloomberg L.P.
Jul 24th, 2023
Sam Altman, Valley VCs Bet $48 Million on Blood-Testing Startup

Years after Theranos, Vital Biosciences wants to prove Silicon Valley really can disrupt blood testing.

INACTIVE